[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] [$pph](/topic/$pph) ### Top Social Posts *Showing only X posts for non-authenticated requests. Use your API key in requests for full results.* "$RHHBY Genentech updates on FDA application for Columvi combo for patients with relapsed or refractory Diffuse Large B-cell Lymphoma. More Info: $XBI $IBB $XPH $PPH" [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946239716480963035) 2025-07-18 16:04:42 UTC 2419 followers, XXX engagements "$SWTX European Commission conditionally approves EZMEKLY (mirdametinib) for treating NF1-PN in adult and pediatric patients. More Info: $XBI $IBB $XPH $PPH" [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946239709015085116) 2025-07-18 16:04:40 UTC 2419 followers, XXX engagements "$ZVRA Zevra Therapeutics to present MIPLYFFA and OLPRUVA at SERGG Annual Meeting. More Info: $XBI $IBB $XPH $PPH" [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946178701269611001) 2025-07-18 12:02:15 UTC 2419 followers, XXX engagements "$OCGN First patient dosed in Phase 2/3 GARDian3 trial for OCU410ST a gene therapy candidate for Stargardt Disease announced by Ocugen Inc. More Info: $XBI $IBB $XPH $PPH" [@OzmosiHealth](/creator/x/OzmosiHealth) on [X](/post/tweet/1946171170883252410) 2025-07-18 11:32:19 UTC 2419 followers, XXX engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Showing only X posts for non-authenticated requests. Use your API key in requests for full results.
"$RHHBY Genentech updates on FDA application for Columvi combo for patients with relapsed or refractory Diffuse Large B-cell Lymphoma. More Info: $XBI $IBB $XPH $PPH"
@OzmosiHealth on X 2025-07-18 16:04:42 UTC 2419 followers, XXX engagements
"$SWTX European Commission conditionally approves EZMEKLY (mirdametinib) for treating NF1-PN in adult and pediatric patients. More Info: $XBI $IBB $XPH $PPH"
@OzmosiHealth on X 2025-07-18 16:04:40 UTC 2419 followers, XXX engagements
"$ZVRA Zevra Therapeutics to present MIPLYFFA and OLPRUVA at SERGG Annual Meeting. More Info: $XBI $IBB $XPH $PPH"
@OzmosiHealth on X 2025-07-18 12:02:15 UTC 2419 followers, XXX engagements
"$OCGN First patient dosed in Phase 2/3 GARDian3 trial for OCU410ST a gene therapy candidate for Stargardt Disease announced by Ocugen Inc. More Info: $XBI $IBB $XPH $PPH"
@OzmosiHealth on X 2025-07-18 11:32:19 UTC 2419 followers, XXX engagements
/topic/$pph/posts